Source:http://linkedlifedata.com/resource/pubmed/id/15474988
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2004-10-11
|
pubmed:abstractText |
Elevated circulating interleukin-6 (IL6) and up-regulated S100P in prostate cancer (PCa) specimens correlate independently with progression to androgen-independent and metastatic PCa. The cause of up-regulated S100P levels in advanced PCa remains to be determined. We investigated the possibility that IL6 is an inducer of S100P. Determination of mRNA and protein levels by real-time PCR and Western blotting revealed that IL6 is a more potent inducer of S100P than the synthetic androgen, R1881, in the LNCaP/C4-2B model of PCa progression. IL6 did not require androgen to induce S100P in these cells, which express a functional androgen receptor (AR). Like R1881, IL6 was unable to induce S100P in PC3 cells that lack a functional AR. IL6 did not strongly induce the AR-dependent genes PSA and KLK2 and, contrary to R1881, down-regulated Cyr61/CCN1, a potential marker that is down-regulated in PCa. Epidermal growth factor (EGF), which like IL6 is a non-androgen activator of the AR, did not induce S100P. The data identifies a unique gene-induction profile for IL6 and suggests that IL6 may require a functional AR for S100P induction. A link between elevated IL6 and up-regulated S100P in androgen-refractory and metastatic PCa is postulated.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Androgens,
http://linkedlifedata.com/resource/pubmed/chemical/Calcium-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6,
http://linkedlifedata.com/resource/pubmed/chemical/Metribolone,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/S100P protein, human
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1357-2725
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
37
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
442-50
|
pubmed:dateRevised |
2008-11-21
|
pubmed:meshHeading |
pubmed-meshheading:15474988-Androgens,
pubmed-meshheading:15474988-Calcium-Binding Proteins,
pubmed-meshheading:15474988-Cell Line, Tumor,
pubmed-meshheading:15474988-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15474988-Humans,
pubmed-meshheading:15474988-Interleukin-6,
pubmed-meshheading:15474988-Male,
pubmed-meshheading:15474988-Metribolone,
pubmed-meshheading:15474988-Neoplasm Metastasis,
pubmed-meshheading:15474988-Neoplasm Proteins,
pubmed-meshheading:15474988-Prostatic Neoplasms,
pubmed-meshheading:15474988-RNA, Messenger,
pubmed-meshheading:15474988-Receptors, Androgen,
pubmed-meshheading:15474988-Transcriptional Activation,
pubmed-meshheading:15474988-Up-Regulation
|
pubmed:year |
2005
|
pubmed:articleTitle |
Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer.
|
pubmed:affiliation |
Bernard O'Brien Institute of Microsurgery, University of Melbourne, 42 Fitzroy Street, Fitzroy, Vic. 3065, Australia. a.hammacher@pgrad.unimelb.edu.au
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|